

ASX RELEASE

12 February 2020

**Initial Director's Interest Notice – Appendix 3X: Dr John Lambert**

Appendix 3X Initial Director's Interest Notice for Dr. John Lambert is attached.

This ASX announcement was approved and authorised for release by the Company Secretary of Amplia Therapeutics Limited.

- End -

**For Further Information**

Andrew J. Cooke  
Company Secretary  
[andrew@ampliatx.com](mailto:andrew@ampliatx.com)  
[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

Name of entity	<b>AMPLIA THERAPEUTICS LIMITED</b>
ABN	<b>16 165 160 841</b>

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	<b>John Nicholas Lambert</b>
Date of appointment	6 February 2020

### Part 1 - Director's relevant interests in securities of which the director is the registered holder *In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>  1,200,000 Options (i) Exercise Price: \$0.165 (ii) 4 years vesting (accelerated upon completion of Phase 1 trial); (iii) Fully vested in a change of control; (iv) Expire 24 June 2024.
--

+ See chapter 19 for defined terms.

## Appendix 3X Initial Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Name of holder & nature of interest	Number & class of Securities
<p>Note: Provide details of the circumstances giving rise to the relevant interest.</p> <p><b>LLAC INVESTMENTS PTY LTD</b>  <b>&lt;RALPH SUPER FUND A/C&gt;</b> of which Mr. Lambert is a Director and beneficiary.</p>	<p>100,000 fully paid shares            50,000 Options – Exercise Price \$0.15 Expiry Date 30 June 2022</p>

### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
No. and class of securities to which interest relates	

12 February 2020

---

+ See chapter 19 for defined terms.